Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771524 | 0.76 | PDE3B (0.42) | PDE3BPDE3AGRIA1 | |
| SCHEMBL4420698 | 0.73 | KMO (0.44) | PDE3BPDE3A | |
| SCHEMBL4427247 | 0.71 | MAPK1 (0.46) | PDE3BPDE3A | |
| SCHEMBL5828007 | 0.69 | DAO (0.35) | — | |
| SCHEMBL4427845 | 0.68 | MAPKAPK2 (0.44) | — | |
| SCHEMBL9038448 | 0.68 | PDE3B (0.42) | PDE3BPDE3ACMA1PGR | |
| SCHEMBL4427818 | 0.67 | CMA1 (0.38) | PDE3BPDE3ACMA1PGRSYK | |
| SCHEMBL4427633 | 0.66 | CHEK1 (0.44) | — | |
| SCHEMBL5337590 | 0.65 | PDGFRB (0.32) | — | |
| SCHEMBL5828401 | 0.65 | GPR84 (0.40) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | PDE3B 179/4885PDE3A 273/4885CMA1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.